Citations

Clear

1792 citation(s) found for "Stephanie".

Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression
O'Hara, Steven P. , Bogert, Pamela Tietz, Dickinson, Stephanie, Chen, Xiwei , Netto, Jair Machado Espindola, Kirkland, James L., Tchkonia, Tamara, Ashraf, Humza M. , Morgenthaler, Olivia , Ali, Ahmad H. , Gores, Gregory J., LaRusso, Nicholas, O’Hara, Steven P. , Bogert, Pamela S., Dickinson, Stephanie, Allison, David B. , Espíndola‐Netto, Jair Machado , Kirkland, James L. , Tchkonia, Tamar , Lazaridis, Konstantinos N. , Gores, Gregory J. , LaRusso, Nicholas F.

Mayo Clinic

Journal of Gastroenterology and Hepatology | February 14, 2026 | Volume: 41 | Issue: 3 | Pages: 1065-1076

10.1111/jgh.70279 | PMID 41689244 Get It

ABSTRACT Background and Aims Cellular senescence is a hallmark of several liver diseases, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Senescent cholangiocytes exhibit a senescence‐associated secretory phenotype (SASP), characterized by profibroinflammatory mediator release. Current cost‐effective biomarkers predicting disease progression, particularly for PSC, are limited and often lack mechanistic relevance. We sought to define a plasma biomarker signature for PSC and PBC. Methods Plasma from early‐ and late‐stage PSC and PBC, alcoholic liver disease (ALD), inflammatory bowel disease (IBD) patients, and healthy controls was analyzed. Seventy‐one analytes were quantified using Luminex Multiplex Immunoassay or enzyme‐linked immunosorbent assay (ELISA). Principal component analysis (PCA) identified key patterns. Findings from the PSC cohort were then applied to additional cohorts. Results Second principal component (PC2) (17 analytes, 17.1% variability) best separated PSC from controls. ANOVA showed significant differences in PC2 between early PSC vs. controls ( p = 0.0001), late PSC vs. controls ( p < 0.0001), and early vs. late PSC ( p < 0.0001). PC2 analytes also distinguished early PBC vs. controls ( p < 0.0332), late PBC ( p < 0.0001), and ALD ( p < 0.0001), and early vs. late PBC ( p < 0.0001), but not IBD vs. controls ( p = 0.119). Logistic regression using PC2 demonstrated strong discrimination of early‐ and late‐stage PSC (AUC = 0.86) and control vs. early‐stage PSC (AUC = 0.83). Conclusion This is the first study to define a plasma SASP biomarker signature associated with cholestatic liver disease. These analytes track disease stage and represent both mechanistic indicators and potential clinical trial endpoints.
Impact of a web‐based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: An Alliance Clinical Trial (A231701CD)
Schumacher, Jessica R. , Hanlon, Bret M., Zahrieh, David , Tucholka, Jennifer L. , McKinney, Grace, Tan, Angelina D., Breuer, Catherine R. , Bailey, Lisa, Higham, Anna M. , Wecsler, Julie S. , Arnold, Alicia H, Froix, Anthony J. , Dull, Scott, Abbott, Andrea M., Fine, Stephanie , McGuire, Kandace P. , Seydel, Anna S. , McNamara, Patricia, Chow, Selina , Neuman, Heather B. , Hanlon, Bret M. , Hanlon, Bret M , Arnold, Alicia , Abbott, Andrea M , Neuman, Heather B , Rathouz, Paul J. , McKinney, Grace, Bailey, Lisa, Abbott, Andrea M.

Mayo Clinic

Cancer | February 11, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70314 | PMID 41669989 Get It

Abstract Objective To test the effectiveness of a surgical web‐based decision aid (DA) in improving knowledge. Summary of Background Data DAs support decision making by providing information about the options. Methods A stepped wedge trial was conducted in 10 National Cancer Institute Community Oncology Research Program clinics (Alliance for Clinical Trials in Oncology). Clinics were randomized to time of transition from usual care (UC) to delivery of a web‐based DA. Patients with stage 0 through 3 breast cancer being considered for surgery were enrolled. Knowledge (primary outcome) was measured using the Breast Cancer Surgery Decision Quality Instrument and patients were asked, “How informed do you feel?” Intervention effects were tested with linear mixed‐effects models, accounting for surgeon and clinic‐level clustering, time, and enrollment after COVID. Additional models controlled for demographics. Results A total of 44% of DA arm patients reviewed the DA and 58% in UC arm reported reviewing “any information.” Being in the DA arm versus UC was not associated with knowledge. However, “review of information” was associated with higher knowledge. In addition, non‐White race and lower education were associated with lower knowledge. The DA arm was associated with higher perceptions of feeling informed (parameter estimate 1.36; 95% CI, 0.18–2.55; p = .02); this persisted even when controlling for review of information or demographics. Conclusion Improved knowledge was not demonstrate with a web‐based DA versus UC. Interestingly, the DA was associated with a higher likelihood of feeling informed. Future research will explore the discrepancy between patients feeling informed but having low knowledge, especially for disadvantaged patients. Trial Registration ClinicalTrials.gov Identifier: NCT0376600
Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Abu-Rustum, Nadeem R, Campos, Susana M. , Amarnath, Sudha R. , Barber, Emma L. , Bradley, Kristin, Brooks, Rebecca , Chon, Hye Sook, Crispens, Marta Ann, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Mantia-Smaldone, Gina , Mariani, Andrea , Mutch, David, Nagel, Christa , Nekhlyudov, Larissa, Nwachukwu, Chika, Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Nwachukwu, Chika , Abu‐Rustum, Nadeem R. , Arend, Rebecca C. , Bradley, Kristin , Chino, Junzo , Crispens, Marta Ann , Gaillard, Stéphanie , Glaser, Gretchen , Landrum, Lisa M. , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 3 | Pages: 101-126

10.6004/jnccn.2026.0011 | PMID 41825134 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vaginal Cancer outline the recommended diagnostic workup, staging considerations, and treatment options for this rare malignancy. Because vaginal cancer is uncommon and shares many biologic and clinical characteristics with cervical cancer, several management recommendations, particularly systemic therapy, are extrapolated from evidence and practices established for cervical cancer. This guideline excerpt summarizes key components of management, including diagnostic evaluation and workup, principles of staging, pathology considerations, radiation therapy principles, and primary treatment recommendations for both early-stage and advanced disease. It also details approaches to manage relapses, including locoregional recurrence and distant metastases, and provides an in-depth overview of systemic therapy recommendations for vaginal cancer.
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Schermerhorn, Sophia M. V. , Vore, Emily , Bondoc, Alexander J, Ayala, Samantha, Kastenberg, Zachary J. , Arkin, Cameron, Malek, Marcus M. , Campwala, Insiyah, Aldrink, Jennifer H. , Horvath, Kyle , Piché, Nelson , Osman, Yasmin, Brown, Erin G, Doyle, Kathleen, Abril, Paige, Roach, Jonathan P, Ziogas, Ioannis A. , Rhee, Daniel S. , Chidiac, Charbel, Debertin, Julia , Craig, Brian T. , Lee, W. N., Barkhordar, Aaron, Joshi, Devashish , Stellon, Michael , Davies, Dafydd A., Boehmer, Chloé , Dasgupta, Roshni, Kastenberg, Zachary J , Arkin, Cameron , Malek, Marcus M , Aldrink, Jennifer H , Horvath, Kyle Z , Polites, Stephanie F. , Lee, William G , Barkhordar, Aaron , Joshi, Devashish , Beckhorn, Catherine , Dasgupta, Roshni , Bondoc, Alexander , Lautz, Timothy B. , Campwala, Insiyah , Brown, Erin G. , Roach, Jonathan P. , Chidiac, Charbel , Lal, Dave R. , Kim, Eugene S. , Le, Hau D. , Tracy, Elisabeth T. , Beckhorn, Catherine B , Dasgupta, Roshni

Mayo Clinic

Cancer | February 7, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70274 | PMID 41653066 Get It

ABSTRACT Background Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
Integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34 ‐mutant reveals universal TP53 abnormalities
Trejo-Lopez, Jorge, Mendoza, Cinthya Zepeda, Kollmeyer, T. M., Decker, P. A., Hardcastle, Jayson, Smoley, Stephanie A., Isaacson, Matthew , Gandham, Mallika , Dasari, Surendra, Raghunathan, Aditya, Giannini, Caterina, Zheng, Gang, Wagner, Aaron S., Lopes, M Beatriz, Fung, K Samuel, Peterson, JoElle, Rivera, Andreana L., Rossi, Christopher , Walsh, Meggen, Abdullaev, Zied , Aldape, Kenneth, Quezado, Martha, Cimino, Patrick Joseph, Jenkins, Robert B, Trejo‐Lopez, Jorge , Trejo-Lopez, Jorge A , Zepeda-Mendoza, Cinthya J , Kollmeyer, Thomas M. , Pazdernik, Vanessa M, Praska, Corinne E, Smoley, Stephanie , Lopes, M Beatriz , Ida, Cristiane M , Zepeda‐Mendoza, Cinthya , Drucker, Kristen , Pazdernik, Vanessa , Praska, Corinne , Dasari, Surendra, Raghunathan, Aditya , Giannini, Caterina , Lopes, M. Beatriz S. , Quezado, Martha , Pratt, Drew , Cimino, Patrick J. , Ida, Cristiane M.

Mayo Clinic

Brain Pathology | February 6, 2026 | Volume: 36 | Issue: 4 | Pages: No page available

10.1111/bpa.70076 | PMID 41649072 Get It

Abstract Diffuse hemispheric glioma, H3 G34‐mutant (DHG‐H3 G34) has been primarily molecularly characterized by methylation profiling and sequencing studies. We describe an integrated histomolecular evaluation including high‐resolution copy number profiling of a series of 60 DHG‐H3 G34 to further our understanding of the spectrum of genetic changes associated with this tumor type. Cases were clinically tested using an 187‐gene mutation and fusion targeted neuro‐oncology next‐generation sequencing panel ( n = 60) and Oncoscan chromosomal microarray ( n = 26) by a single laboratory (2018–2022). A subset of cases had immunohistochemical results for OLIG2 ( n = 42), p53 ( n = 48), and ATRX ( n = 46), and methylation array data ( n = 8). Median age at testing was 21 years (range, 12–50). No significant difference was noted in clinical, histopathological, and mutational profile between pediatric and adult patients. H3‐3A G34 mutations included G34R ( n = 56; 94%), G34V ( n = 3), and a non‐canonical G34E ( n = 1). Concurrent mutations most often involved TP53 ( n = 55; 92%), ATRX ( n = 50; 83%), and PDGFRA ( n = 34; 57%). A reportedly primary tumor was confirmed to be hypermutant and had a PMS2 mutation. A single case also showed an FGFR3::FAM184B fusion. All cases with available chromosomal microarray data had unbalanced genomes, which were often complex (14/26; 54%). The most frequent recurrent copy number abnormalities were losses involving 3q, 4q, 10q, 13q, and 18q, and 17p copy‐neutral loss of heterozygosity (cnLOH) encompassing TP53 . This copy number profile was reminiscent of that seen in Grade 4 IDH‐mutant astrocytomas. Collectively, a TP53 abnormality at copy number (12/26, all cnLOH), sequence (55/60) and protein expression (46/48) level was detected in all 60 cases. In conclusion, integrated high‐resolution copy number and histomolecular analysis expanded the spectrum of genetic changes associated with DHG‐H3 G34, including the presence of universal TP53 abnormalities with frequent cnLOH—a copy number abnormality that has been largely unrecognized—for this new 2021 World Health Organization central nervous system tumor type.
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Srinagesh, Hrishikesh K. , Zhang, Amy, Grunwald, Michael R, Connor, Matthew P, Kota, Vamsi, Boccucci, Jacob , Ulrickson, M., Pradeep, Roshini , Hill, L, Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Sandhu, Karamjeet , Gordillo, Christian , Chen, Evan C., Lin, Chenyu, Kopmar, Noam E. , Majhail, Navneet S. , Lee, C F, Bobillo, Silvina Odstrcil, Park, Jae H, Valtis, Yannis K. , Solh, Melhem M, Guzowski, Caitlin, Vasu, Sumithira, Tan, Virginia, McCauley, Ross , Sasine, Joshua , Tang, Kevin, Kk, Miller, Sutherland, Katherine C. , Mohty, Razan , Jamy, Omer , Hoeg, Rasmus T., Logan, Aaron, Stock, Wendy A, Schwartz, Marc S., Byrd, Kenneth, Bachanova, Veronika, Tracy, Sean , Yaghmour, George , Gatell, Vivian Irizarry , Jackson, Clayton, Dholaria, Bhagirathbhai, O'Dwyer, Kristen M, Moore, Jozal , Aldoss, Ibrahim, Shah, B. D., Oliai, Caspian , Muffly, Lori, Grunwald, Michael R. , Kota, Vamsi , Bachanová, Veronika , Muffly, Lori , Hill, LaQuisa C. , Zhang, Amy , Connor, Matthew P. , Zhang, Amy , Grunwald, Michael , Connor, Matthew , Kota, Vamsi , Ulrickson, Matthew , Pradeep, Roshini , Hill, LaQuisa C , Advani, Anjali S , Reshef, Ran , Luskin, Marlise R , Chen, Evan , Lin, Chenyu , Cassaday, Ryan D , Kopmar, Noam E , Majhail, Navneet S , Battiwalla, Minoo , Strickland, Stephen Anthony , Lee, Catherine J , Odstrcil Bobillo, Silvina , Hilal, Talal , Faramand, Rawan , Leonard, Jessica T , Wang, Eunice S. , Sasine, Joshua , Sutherland, Katherine , Daunov, Michael , Jamy, Omer , Dykes, Kaitlyn C , Logan, Aaron C , Othman, Tamer , Stock, Wendy , Yalniz, Fevzi , Bachanova, Veronika , Irizarry Gatell, Vivian M , Oluwole, Olalekan O , Dholaria, Bhagirathbhai R , O'Dwyer, Kristin , Moore, Jozal , Roloff, Gregory W , Frey, Noelle V , Shah, Bijal , Oliai, Caspian H , Muffly, Lori , Gupta, Vishal , Ulrickson, Matthew L. , Tsai, Stephanie, Advani, Anjali S. , Reshef, Ran , Lin, Chenyu , Cassaday, Ryan D. , Battiwalla, Minoo , Bobillo, María Silvina Odstrcil , Hilal, Talal , Park, Jae H. , Faramand, Rawan , Solh, Melhem , Vasu, Sumithira , Daunov, Michael , Kumaran, Muthu Sendhil , Hoeg, Rasmus T. , Dykes, Kaitlyn C. , Othman, Tamer , Stock, Wendy , Byrd, Kenneth, Yalniz, Fevzi , Jackson, Clayton W., Oluwole, Olalekan O. , Dholaria, Bhagirathbhai , Roloff, Gregory W. , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood | February 5, 2026 | Volume: 147 | Issue: 17 | Pages: 2011-2017

10.1182/blood.2025031734 | PMID 41643192 Get It

Abstract In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.
Evaluating treatment effectiveness: Complementing RCTs with real-world data
Mozaffari, Essy, Rivera, Christina G. , Read, Stephanie H. , Kalil, André C.

Mayo Clinic

American Journal of Health-System Pharmacy | February 5, 2026 | Volume: 83 | Issue: Supplement_3 | Pages: S2909-S2914

10.1093/ajhp/zxag035 | PMID 41656514 Get It

Abstract Purpose While randomized controlled trials remain the gold standard for assessing treatment efficacy, studies using real-world data (RWD) offer valuable insights into treatment effectiveness across broader, more diverse patient populations. This commentary explores the importance of using fit-for-purpose data and emphasizes the need for rigorous evaluation of RWD quality to support valid and actionable evidence generation. Summary The utility of RWD-based studies depends heavily on the fitness-for-purpose of the data source, which requires careful assessment of 5 key quality dimensions: relevance, extensiveness, timeliness, coherence, and reliability. Practical examples from coronavirus disease 2019 (COVID-19) comparative effectiveness research are used to illustrate each data quality domain. Conclusions As the need for RWD increases, especially for post–COVID-19 pandemic decision-making, ensuring high data quality and appropriate study design is critical. Proper evaluation of RWD sources enhances the credibility of findings and supports their use in meta-analyses, clinical guidelines, and healthcare policy.
ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment
Song, Nuozi , Chen, Siqi, Wang, Lei , Dang, Jessica, Singh, Stephanie, Yang, Lu, Rosen, Steven T., Wang, Yingyu, Chen, Chun‐Wei D., Zhang, Cheng, Feng, Mingye , Chen, Chun‐Wei , Feng, Mingye , Chen, Chun-Wei , Dang, Jessica, Cao, Xu , Wang, Jinhui , Rosen, Steven T.

Mayo Clinic

Advanced Science | February 3, 2026 | Volume: 13 | Issue: 20 | Pages: No page available

10.1002/advs.202513672 | PMID 41632816 Get It

ABSTRACT Tumorigenesis and metastasis are frequently attributed to the intricate interplay between cancer cells and the tumor microenvironment (TME). Comprehending the mechanisms and key regulators of cancer‐immune crosstalk in the TME is imperative for developing efficacious immunotherapy. Through a series of in vivo CRISPR screens, we identified tumor‐intrinsic ITGB1 as a critical regulator of triple‐negative breast cancer (TNBC) development and deciphered its underlying mechanisms. Tumoral ITGB1 facilitated the establishment of pro‐tumorigenic TME by orchestrating tumor‐associated myeloid populations. Suppressing ITGB1 favored the enrichment of anti‐tumorigenic myeloid cells and enhanced infiltration of CD4 and CD8 T cells, culminating in superior antitumor effects. CRISPR scanning pinpointed a previously unrecognized functional domain essential for ITGB1's pro‐tumorigenic activity. This domain is distinct from all known ligand‐binding sites in ITGB1. An antibody capable of sterically blocking this domain significantly impaired TNBC progression. These findings position tumoral ITGB1 as a promising therapeutic target for reprogramming the TME from a pro‐ to an anti‐tumorigenic state, thereby effectively inhibiting TNBC development. Our study uncovers a novel mechanism of TNBC development and provides a unique therapeutic strategy for targeting ITGB1 in TNBC treatment.
Using wearable and nearable devices in telerehabilitation for COPD: a scoping review of digital endpoints in home-based programs
Collins, Caden , Enayati, Moein , Benzo, Roberto, Fortune, Emma , Faust, Louis , Zawada, Stephanie , Benzo, Roberto P.

Mayo Clinic

Frontiers in Digital Health | February 3, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fdgth.2026.1698019 | PMID 41710266 Get It

Introduction Despite its demonstrated effectiveness at improving outcomes, pulmonary rehabilitation (PR) for chronic obstructive pulmonary disease (COPD) is underutilized. Sensor-generated data from wearable devices have the potential to mitigate this challenge by generating digital endpoints that provide insights into patient behaviors at home; however, there is no consensus on how to measure home-based PR (HBPR) outcomes with these tools. This review aims to describe (1) the most frequent digital endpoints used in HBPR studies and (2) the devices used to capture these endpoints, summarizing gaps in their applications to HBPR for COPD patients. Methods We completed a scoping review using the PRISMA checklist across databases (Web of Science, Scopus, and OVID) from January 1, 2005 to June 1, 2025. We included peer-reviewed articles on HBPR for COPD, excluding reviews, commentaries/editorials, poster abstracts, and conference proceedings. Eligible articles included cohort studies and clinical trials of adult patients (age ≥ 18 years) with COPD participating in HBPR that include one or more digital endpoints. Results Among eligible articles ( n = 218), 13 (6.0%) met inclusion criteria, the majority of which were published after 2020 (61.5%). Most studies enrolled fewer than 100 COPD patients (76.9%) for an average monitoring period of 12.5 weeks. Activity trackers were the most commonly used device (46.2%) to capture data. The most frequently used digital endpoints were step count (84.6%), time spent active (38.5%), and time spent sedentary (30.8%). Two study designs were used: randomized controlled trial (76.9%) and observational cohort. Study designs were heterogenous with more than one-third (38.5%) presenting a lack of statistically significant results. Discussion Although we identified analogous digital endpoints in some studies, dissimilar methods and study designs remain barriers to synthesizing results generated from HBPR programs for COPD. Wearable devices have the potential to build novel PR models, but more work is needed to translate real-world data into clinically meaningful measures. Future research should elucidate which participants would benefit most from and complete HBPR to build an evidence base for the validation of HBPR-relevant digital endpoints, particularly those derived from less common sources like cardiovascular and sleep measures.
Global perspectives on perimenopause: a digital survey of knowledge and symptoms using the Flo application
Hedges, Mary S. , Martin, Yella , Karam, Jana , Castaneda, Regina , Xu, Yihan, Shufelt, Chrisandra , Xu, Yihan , Shufelt, Chrisandra L , Hedges, Mary S , Castaneda, Regina , Hewings-Martin, Yella , Cunningham, Adam , Xu, Yihan , Zhaunova, Liudmila , Faubion, Stephanie S.

Mayo Clinic

Menopause | January 28, 2026 | Volume: 33 | Issue: 7 | Pages: 789-798

10.1097/gme.0000000000002730 | PMID 41603602 Get It

Objective: Perimenopause is the time leading up to a woman’s last menstrual cycle and includes the 12 months afterward. Studies that systematically compare perimenopause symptoms across diverse cultural and geographic settings are lacking. This study, utilizing data from Flo, an international mobile health application, aimed to assess global knowledge and symptom experiences related to perimenopause. Methods: This cross-sectional survey was conducted via the Flo application, offered to users aged 18 years and above. The primary endpoints were knowledge of perimenopause symptoms from all survey participants, and self-reported perimenopause symptoms for survey participants aged 35 years and above. Secondary analyses compared knowledge scores and symptoms across geographic regions. Results: A total of 17,494 women from 158 countries were included. Commonly recognized perimenopause symptoms included hot flashes (71%), sleep problems (68%), and weight gain (65%). Of the participants, 12,681 were aged 35 years or above, with the most common self-reported symptoms being fatigue (83%), physical and mental exhaustion (83%), irritability (80%), depressive mood (77%), sleep problems (76%), digestive issues (76%), and anxiety (75%). This pattern of symptoms was similar among those who self-reported being in perimenopause, though higher than in those not in perimenopause. International variation in perimenopause symptom knowledge and symptoms experienced was noted ( P <0.001). Conclusions: This survey highlights a discordance between perimenopause knowledge and actual symptoms experienced across diverse global populations. While hot flashes were the most widely recognized symptom, respondents aged 35 years or above most commonly reported experiencing fatigue, physical and mental exhaustion, and irritability.